Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1Breast 1

Conditions

Small Cell Lung Carcinoma 3Carcinoma, Non-Small-Cell Lung 2Neoplasm Metastasis 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Radiosurgery 27Radiotherapy 17Magnetic Resonance Spectroscopy 14Erlotinib Hydrochloride 14Bevacizumab 13Pemetrexed 10Carboplatin 10pembrolizumab 9Gefitinib 9osimertinib 8icotinib 7Temozolomide 7Nivolumab 6Specimen Handling 5Paclitaxel 5Spermine Synthase 4Mental Status and Dementia Tests 4Ipilimumab 4Drug Therapy 4Cisplatin 4atezolizumab 3alectinib 3aflutinib 3Radiation 3Immunotherapy 3Fluorodeoxyglucose F18 3regorafenib 2paclitaxel-Angiopep-2 conjugate 2motexafin gadolinium 2epothilone B 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × etirinotecan pegol × Thoracic × Clear all
NCT02312622 2023-12-12

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Stanford University

Phase 2 Completed
27 enrolled 19 charts
BreastCNSThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡